Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 08 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide tablets. The tablets are indicated for the treatment of high blood pressure and will be manufactured at the company's facility in Ahmedabad. The press release also notes that the drug had significant annual sales in the United States according to market data.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases